Versant Ventures and RA Capital Management have led a €66m series-A funding round for T-knife, an adoptive T-cell therapy developer based in Germany.
Versant Ventures and RA Capital Management have led a €66m series-A funding round for T-knife, an adoptive T-cell therapy developer based in Germany.